Clinical Trial Update: Gelsemium Sempervirens in Anticipatory Anxiety [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Gelsemium sempervirens for anticipatory anxiety has completed. The study was sponsored by University Hospital, Grenoble.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety

Drugs mentioned

• Gelsemium Sempervirens (Gelsemium sempervirens)

Snippet

Sponsor: University Hospital, Grenoble | Conditions: Anxiety | Phase 3 | Status: COMPLETED